PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Войти

Зарегистрироваться
Забыли пароль?

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

IMG-20170802-WA0012
20180202 160137
IMG-20170807-WA0002
IMG-20170807-WA0034
DJI 0031
20170802 170633
  • CDER Data Standards Program
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-17 By FDA
  • Data Standards Program Strategic Plan and Board
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-17 By FDA
  • Human medicines European public assessment report (EPAR): Tryngolza, olezarsen, Date of authorisation: 17/09/2025, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-17
  • Human medicines European public assessment report (EPAR): Izamby, denosumab, Date of authorisation: 26/06/2025, Revision: 1, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-17
  • Human medicines European public assessment report (EPAR): Mynzepli, aflibercept, Date of authorisation: 18/08/2025, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-17
  • Patient-Focused Drug Development: Workshop #2 to Discuss Methodologic and Other Challenges Related to Patient Experience Data - 09/18/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-17 By FDA
  • Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 29, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-17
  • Human medicines European public assessment report (EPAR): Qoyvolma, ustekinumab, Date of authorisation: 02/06/2025, Revision: 2, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-17
  • Human medicines European public assessment report (EPAR): Kavigale, sipavibart, Date of authorisation: 20/01/2025, Revision: 2, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-17
  • Human medicines European public assessment report (EPAR): Otulfi, ustekinumab, Date of authorisation: 25/09/2024, Revision: 4, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-17
  • Human medicines European public assessment report (EPAR): Sapropterin Dipharma, sapropterin, Date of authorisation: 16/02/2022, Revision: 6, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-17
  • Human medicines European public assessment report (EPAR): Tecartus, brexucabtagene autoleucel, Date of authorisation: 14/12/2020, Revision: 14, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-17
  • Human medicines European public assessment report (EPAR): Polivy, polatuzumab vedotin, Date of authorisation: 16/01/2020, Revision: 7, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-17
  • Human medicines European public assessment report (EPAR): Brinsupri, Brensocatib, Status: Opinion
    Source: EMA - New medicines: human Published on 2025-10-17
  • Human medicines European public assessment report (EPAR): Wayrilz, rilzabrutinib, Status: Opinion
    Source: EMA - New medicines: human Published on 2025-10-17
Предыдущие записи
Тема: Scaffold от Danny Cooper.